Replies to post #78643 on PharmaCyte Biotech Inc (PMCB)

[mick]

MATTER OF TIME , MATTER OF TIMING /////\\\\\

[AJ_invest]

This is a "paid for" article..

Says at the bottom "The company paid consideration to SNN or its affiliates for this article". If this were news it should be done in a press release.

This "article" says that "The trial will be conducted in the U.S. and Europe by premiere oncology CRO, Translational Drug Development (TD2).
I thought they said that they have broken away from TD2 as their CRO???

How is this sticky? Come on man...